Loading...
•
Sep 30, 2022
Twist Bioscience Q4 2022 Earnings Report
Reported record revenue and continued laying foundation for growth.
Key Takeaways
Twist Bioscience reported a revenue of $57.3 million for the fourth quarter of fiscal year 2022, compared to $38.0 million for the same period of fiscal year 2021. The net loss attributable to common stockholders for the fourth quarter of fiscal 2022 was $51.1 million, or $0.91 per share, compared to $41.2 million, or $0.84 per share, for the same period of fiscal 2021.
Total orders received for fiscal 2022 were $226 million compared to $159.5 million for fiscal 2021.
Total revenues for fiscal 2022 were $203.6 million compared to $132.3 million for fiscal 2021.
Shipped products to approximately 3,300 customers in fiscal 2022, versus approximately 2,900 in fiscal 2021.
The Factory of the Future is on track to ship products in January 2023 and company plans to launch first DNA data storage solution as an early access offering in late calendar 2023.
Twist Bioscience
Twist Bioscience
Forward Guidance
Twist Bioscience provided financial guidance for the full fiscal year 2023 and 2024, including the first quarter of fiscal 2023.
Positive Outlook
- Revenue is expected to be in the range of $261 million to $269 million for fiscal year 2023
- SynBio revenue is expected to be in the range of $104 million to $106 million for fiscal year 2023
- NGS revenue is expected to be in the range of $120 million to $123 million for fiscal year 2023
- Biopharma revenue is expected to be in the range of $37 million to $40 million for fiscal year 2023
- Revenue is expected to be approximately $350 million for fiscal year 2024
Challenges Ahead
- Net loss is expected to be approximately $260 million for fiscal year 2023
- Operating loss is expected to be approximately $215 million for fiscal year 2024
- Operating expenses for DNA data storage of approximately $46 million for fiscal year 2023
- Operating expenses for DNA data storage of approximately $57 million for fiscal year 2024
- FY24 Year End Cash projected to be $170M